CETSA® Navigate HT: A new paradigm for high-throughput screening

Wed20  Oct12:30pm(15 mins)
Room 3A
 Fredrik Rahm


For a drug compound to be efficacious and safe, it must selectively bind to its intended target protein at the intended site of action. A significant portion of projects fail in the clinic due to lack of efficacy or failure to show that the drug candidate interacts with the intended target in a complex biological context. Too often, target engagement assessments are introduced late in drug discovery and development projects with increased risk of late-stage failures as a consequence.

Applications of the proven CEllular Thermal Shift Assay (CETSA®) technology to assess target engagement in various matrixes are increasingly used for SAR studies and lead optimisation efforts. By the introduction of the high-throughput format, CETSA® Navigate HT, this technology has proven to be a powerful tool already in the hit identification phase. Due to its broad applicability to native, full length protein targets in the live cellular environment, without the need for expensive and time-consuming protein and/or compound labelling efforts, CETSA® Navigate HT may be regarded as a new paradigm for high-throughput screening.
To view the video assoicated with this lecture click here

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2021